Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Hoppe, 2020, Hodgkin lymphoma, version 2.2020, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 18, 755, 10.6004/jnccn.2020.0026 Canellos, 1992, Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD, N Engl J Med, 327, 1478, 10.1056/NEJM199211193272102 Behringer, 2005, Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group, J Clin Oncol, 23, 7555, 10.1200/JCO.2005.08.138 Andre, 2020, Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: a pooled analysis of four randomized trials, Cancer Med, 9, 6565, 10.1002/cam4.3298 Stephens, 2019, Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma, Blood, 134, 1238, 10.1182/blood.2019000719 Ansell, 2012, Positron emission tomographic scans in lymphoma: convention and controversy, Mayo Clin Proc, 87, 571, 10.1016/j.mayocp.2012.03.006 Connors, 2018, Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma, N Engl J Med, 378, 331, 10.1056/NEJMoa1708984 Straus, 2020, Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study, Blood, 135, 735, 10.1182/blood.2019003127 Straus, 2020, Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy, Leuk Lymphoma, 61, 2931, 10.1080/10428194.2020.1791846 Hapgood, 2016, Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia, J Clin Oncol, 34, 2493, 10.1200/JCO.2015.65.4194 Radford, 1997, Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records, BMJ, 314, 343, 10.1136/bmj.314.7077.343a Johnson, 2016, Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma, N Engl J Med, 374, 2419, 10.1056/NEJMoa1510093 Gallamini, 2018, Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial, J Clin Oncol, 36, 454, 10.1200/JCO.2017.75.2543 Borchmann, 2018, PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group, Lancet, 390, 2790, 10.1016/S0140-6736(17)32134-7 Casasnovas, 2019, PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study, Lancet Oncol, 20, 202, 10.1016/S1470-2045(18)30784-8 Evens, 2012, A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era, Blood, 119, 692, 10.1182/blood-2011-09-378414 Trotman, 2017, Response-adjusted therapy for advanced Hodgkin lymphoma (RATHL) trial: longer follow up confirms efficacy of de-escalation after a negative interim PET scan (CRUK/07/033), Hematol Oncol, 35, 65, 10.1002/hon.2437_53 Anderson, 2018, Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial, Lancet Oncol, 19, 1328, 10.1016/S1470-2045(18)30500-X Hodgson, 2007, Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma, J Clin Oncol, 25, 1489, 10.1200/JCO.2006.09.0936 Behringer, 2013, Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials, J Clin Oncol, 31, 231, 10.1200/JCO.2012.44.3721 Bujan, 2014, Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network, Fertil Steril, 102, 667, 10.1016/j.fertnstert.2014.06.008 Sieniawski, 2008, Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG), Blood, 111, 71, 10.1182/blood-2007-02-073544 Casasnovas, 2020, PET-guided strategy improves the safety of BEACOPP-based treatment in advanced Hodgkin lymphoma: prolonged follow-up of the LYSA AHL 2011 phase 3 study, Blood, 136, 475 Eichenauer, 2017, Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials, Haematologica, 102, 1748, 10.3324/haematol.2017.167478 Danylesko, 2018, Second malignancies after hematopoietic stem cell transplantation, Curr Treat Options Oncol, 19, 9, 10.1007/s11864-018-0528-y Kreissl, 2020, PET-guided treatment in patients with advanced-stage Hodgkin lymphoma: follow-up analysis of PET-2-negative patients in the HD18 trial by the German Hodgkin study group, HemaSphere, 4, 69 Castellino, 2020, An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826, Proc Am Soc Clin Oncol, 38 Friedman, 2020, Brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in newly diagnosed patients with advanced-stage Hodgkin lymphoma (trial in progress), Proc Am Soc Clin Oncol, 38